{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T19:48:19Z","timestamp":1788378499635,"version":"build-2803163510"},"reference-count":130,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Med. Chem."],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.4155\/fmc.12.29","type":"journal-article","created":{"date-parts":[[2012,4,24]],"date-time":"2012-04-24T17:38:57Z","timestamp":1335289137000},"page":"799-822","source":"Crossref","is-referenced-by-count":48,"title":["An Update On Dual Src\/Abl Inhibitors"],"prefix":"10.1080","volume":"4","author":[{"given":"Francesca","family":"Musumeci","sequence":"first","affiliation":[{"name":"Dipartimento di Scienze Farmaceutiche, University of Genoa, Viale Benedetto XV 3, I-16132Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Schenone","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Farmaceutiche, University of Genoa, Viale Benedetto XV 3, I-16132Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Brullo","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Farmaceutiche, University of Genoa, Viale Benedetto XV 3, I-16132Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Botta","sequence":"additional","affiliation":[{"name":"Dipartimento Farmaco Chimico Tecnologico, University of Siena, Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2012,4,24]]},"reference":[{"key":"e_1_3_2_2_1_1","first-page":"745","article-title":"Bcr-Abl and Bcr proteins: biochemical characterization and localization.","volume":"4","author":"Dhut S","year":"1990","unstructured":"Dhut S , ChaplinT, YoungBD. Bcr-Abl and Bcr proteins: biochemical characterization and localization.Leukemia4, 745\u2013750 (1990).","journal-title":"Leukemia"},{"key":"e_1_3_2_2_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(03)00194-6"},{"key":"e_1_3_2_2_3_1","doi-asserted-by":"publisher","DOI":"10.2174\/138955707779802598"},{"key":"e_1_3_2_2_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203912"},{"key":"e_1_3_2_2_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng1343"},{"key":"e_1_3_2_2_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/cdf562"},{"key":"e_1_3_2_2_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-1131"},{"key":"e_1_3_2_2_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/med.20175"},{"key":"e_1_3_2_2_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2126"},{"key":"e_1_3_2_2_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-4889(99)00075-0"},{"key":"e_1_3_2_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90405-F"},{"key":"e_1_3_2_2_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/359851a0"},{"key":"e_1_3_2_2_13_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1280858"},{"key":"e_1_3_2_2_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208081"},{"key":"e_1_3_2_2_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2008.12.024"},{"key":"e_1_3_2_2_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(00)80356-1"},{"key":"e_1_3_2_2_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2005.03.012"},{"key":"e_1_3_2_2_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/19.5.964"},{"key":"e_1_3_2_2_19_1","doi-asserted-by":"publisher","DOI":"10.2174\/157488508785747862"},{"key":"e_1_3_2_2_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm1280"},{"key":"e_1_3_2_2_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(02)00623-2"},{"key":"e_1_3_2_2_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng0398-280"},{"key":"e_1_3_2_2_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205017"},{"key":"e_1_3_2_2_24_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.0040144"},{"key":"e_1_3_2_2_25_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M005401200"},{"key":"e_1_3_2_2_26_1","first-page":"4244","article-title":"Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases.","volume":"62","author":"Wisniewski D","year":"2002","unstructured":"Wisniewski D , LambekCL, LiuCet al. Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Res. 62, 4244\u20134255 (2002).","journal-title":"Cancer Res."},{"key":"e_1_3_2_2_27_1","first-page":"117","article-title":"Structure of the Bcr-Abl oncoprotein oligomerization domain.","volume":"9","author":"Zhao X","year":"2002","unstructured":"Zhao X , GhaffariS, LodishH, MalashkevichVN, KimPS. Structure of the Bcr-Abl oncoprotein oligomerization domain.Nat. Struct. Biol.9, 117\u2013120 (2002).","journal-title":"Nat. Struct. Biol."},{"key":"e_1_3_2_2_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2003.10.005"},{"key":"e_1_3_2_2_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.8.2957"},{"key":"e_1_3_2_2_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2004.11.019"},{"key":"e_1_3_2_2_31_1","first-page":"1267","article-title":"A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants.","volume":"9","author":"Huron DR","year":"2003","unstructured":"Huron DR , GorreME, KrakerAJ, SawyersCL, RosenN, MoasserMM. A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants.Clin. Cancer Res.9, 1267\u20131273 (2003).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_2_2_32_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-05-0101"},{"key":"e_1_3_2_2_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio799"},{"key":"e_1_3_2_2_34_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm901443h"},{"key":"e_1_3_2_2_35_1","doi-asserted-by":"publisher","DOI":"10.2174\/092986710790936310"},{"key":"e_1_3_2_2_36_1","doi-asserted-by":"publisher","DOI":"10.4161\/cc.9.18.13232"},{"key":"e_1_3_2_2_37_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.2.695"},{"key":"e_1_3_2_2_38_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M209321200"},{"key":"e_1_3_2_2_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-010-0632-1"},{"key":"e_1_3_2_2_40_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm049486a"},{"key":"e_1_3_2_2_41_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099480"},{"key":"e_1_3_2_2_42_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0259"},{"key":"e_1_3_2_2_43_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0702654104"},{"key":"e_1_3_2_2_44_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4187"},{"key":"e_1_3_2_2_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.9260"},{"key":"e_1_3_2_2_46_1","first-page":"49","article-title":"Staging and prognosis in chronic myelogenous leukemia.","volume":"25","author":"Sokal JE","year":"1988","unstructured":"Sokal JE , BaccaraniM, RussoD, TuraS. Staging and prognosis in chronic myelogenous leukemia.Semin. Hematol.25, 49\u201361 (1988).","journal-title":"Semin. Hematol."},{"key":"e_1_3_2_2_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"e_1_3_2_2_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4920"},{"key":"e_1_3_2_2_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.3339"},{"key":"e_1_3_2_2_50_1","doi-asserted-by":"publisher","DOI":"10.1177\/147323001103900201"},{"key":"e_1_3_2_2_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-073528"},{"key":"e_1_3_2_2_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21615"},{"key":"e_1_3_2_2_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.7231"},{"key":"e_1_3_2_2_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-140665"},{"issue":"2","key":"e_1_3_2_2_55_1","article-title":"Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059.","volume":"69","author":"Finn RS","year":"2009","unstructured":"Finn RS , BengalaC, IbrahimNet al. Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059. Cancer Res. 69(2 Suppl.), (Abstract 3118) (2009).","journal-title":"Cancer Res."},{"key":"e_1_3_2_2_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605101"},{"key":"e_1_3_2_2_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2011.01.006"},{"key":"e_1_3_2_2_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.5474"},{"key":"e_1_3_2_2_59_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181cee36e"},{"key":"e_1_3_2_2_60_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4029"},{"key":"e_1_3_2_2_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25410"},{"key":"e_1_3_2_2_62_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.03.034"},{"key":"e_1_3_2_2_63_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm0102250"},{"key":"e_1_3_2_2_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2005.04.065"},{"key":"e_1_3_2_2_65_1","first-page":"375","article-title":"SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.","volume":"63","author":"Golas JM","year":"2003","unstructured":"Golas JM , ArndtK, EtienneCet al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. 63, 375\u2013381 (2003).","journal-title":"Cancer Res."},{"key":"e_1_3_2_2_66_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-1199"},{"key":"e_1_3_2_2_67_1","article-title":"An ongoing phase 3 study of bosutinib (SKI-606) versus imatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia.","volume":"116","author":"Gambacorti-Passerini C","year":"2010","unstructured":"Gambacorti-Passerini C , KimDW, KantarjianHMet al. An ongoing phase 3 study of bosutinib (SKI-606) versus imatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia. Blood (ASH Annual Meeting Abstracts) 116, (Abstract 208) (2010).","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"18","key":"e_1_3_2_2_68_1","first-page":"3552","article-title":"Bosutinib (SKI-606), a dual Src\/Abl tyrosine kinase inhibitor: Preliminary results from a phase 1 study in patients with advanced malignant solid tumors.","volume":"25","author":"Messersmith WA","year":"2007","unstructured":"Messersmith WA , KrishnamurthiS, HewesBAet al. Bosutinib (SKI-606), a dual Src\/Abl tyrosine kinase inhibitor: Preliminary results from a phase 1 study in patients with advanced malignant solid tumors. J. Clin. Oncol. 2007 ASCO Annual Meeting Proceedings 25(18S), 3552 (2007).","journal-title":"J. Clin. Oncol. 2007 ASCO Annual Meeting Proceedings"},{"key":"e_1_3_2_2_69_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr261"},{"key":"e_1_3_2_2_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2010.412"},{"key":"e_1_3_2_2_71_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-09-0962"},{"key":"e_1_3_2_2_72_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLC.2010.n.030"},{"key":"e_1_3_2_2_73_1","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/530130"},{"key":"e_1_3_2_2_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2010.03.025"},{"key":"e_1_3_2_2_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2009.01.002"},{"key":"e_1_3_2_2_76_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm060434q"},{"key":"e_1_3_2_2_77_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-9-53"},{"key":"e_1_3_2_2_78_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-008-0058-6"},{"key":"e_1_3_2_2_79_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-010-1024-7"},{"key":"e_1_3_2_2_80_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.250"},{"key":"e_1_3_2_2_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.08249.x"},{"key":"e_1_3_2_2_82_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31819c78fb"},{"key":"e_1_3_2_2_83_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.090830"},{"issue":"18","key":"e_1_3_2_2_84_1","first-page":"3520","article-title":"I study of AZD0530, an oral potent inhibitor of Src kinase: First demonstration of inhibition of Src activity in human cancers.","volume":"25","author":"Tabernero J","year":"2007","unstructured":"Tabernero J , CervantesA, HoekmanKet al. I study of AZD0530, an oral potent inhibitor of Src kinase: First demonstration of inhibition of Src activity in human cancers. J. Clin. Oncol. 2007 ASCO Annual Meeting Proceedings 25(18S), 3520 (2007).","journal-title":"J. Clin. Oncol. 2007 ASCO Annual Meeting Proceedings"},{"key":"e_1_3_2_2_85_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-08-0219"},{"key":"e_1_3_2_2_86_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-2511"},{"key":"e_1_3_2_2_87_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-3021"},{"key":"e_1_3_2_2_88_1","first-page":"249","article-title":"Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).","volume":"31","author":"Fury MG","year":"2011","unstructured":"Fury MG , BaxiS, ShenRet al. Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Anticancer Res. 31, 249\u2013253 (2011).","journal-title":"Anticancer Res."},{"key":"e_1_3_2_2_89_1","first-page":"4236","article-title":"Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).","volume":"62","author":"Nagar B","year":"2002","unstructured":"Nagar B , BornmannWG, PellicenaPet al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62, 4236\u20134243 (2002).","journal-title":"Cancer Res."},{"key":"e_1_3_2_2_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2009.10.085"},{"key":"e_1_3_2_2_91_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-05-1851"},{"key":"e_1_3_2_2_92_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0600001103"},{"key":"e_1_3_2_2_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2008.06.042"},{"key":"e_1_3_2_2_94_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1747-0285.2009.00905.x"},{"key":"e_1_3_2_2_95_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm900166t"},{"key":"e_1_3_2_2_96_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1747-0285.2009.00911.x"},{"key":"e_1_3_2_2_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.09.028"},{"key":"e_1_3_2_2_98_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm100395q"},{"key":"e_1_3_2_2_99_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1747-0285.2010.01054.x"},{"key":"e_1_3_2_2_100_1","doi-asserted-by":"publisher","DOI":"10.2174\/092986708786848613"},{"key":"e_1_3_2_2_101_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-10-1044"},{"key":"e_1_3_2_2_102_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-326843"},{"key":"e_1_3_2_2_103_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI35721"},{"key":"e_1_3_2_2_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2011.04.060"},{"key":"e_1_3_2_2_105_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-251751"},{"key":"e_1_3_2_2_106_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.107"},{"key":"e_1_3_2_2_107_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-10-0232"},{"key":"e_1_3_2_2_108_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-3953"},{"key":"e_1_3_2_2_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2010.01.008"},{"key":"e_1_3_2_2_110_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802709438"},{"key":"e_1_3_2_2_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.07.041"},{"key":"e_1_3_2_2_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6349(06)70176-8"},{"key":"e_1_3_2_2_113_1","article-title":"Targeting drug-resistant CML and Ph+-ALL with the spectrum selective protein kinase inhibitor XL228.","volume":"110","author":"Shah NP","year":"2007","unstructured":"Shah NP , KasapC, PaquetteRet al. Targeting drug-resistant CML and Ph+-ALL with the spectrum selective protein kinase inhibitor XL228. Blood (ASH Annual Meeting Abstracts) 110, (2007) (Abstract 474).","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_3_2_2_114_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja900871y"},{"key":"e_1_3_2_2_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymeth.2003.10.007"},{"key":"e_1_3_2_2_116_1","doi-asserted-by":"publisher","DOI":"10.1039\/C0MB00108B"},{"key":"e_1_3_2_2_117_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm050603r"},{"key":"e_1_3_2_2_118_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm701240c"},{"key":"e_1_3_2_2_119_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm061449r"},{"key":"e_1_3_2_2_120_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2010.499898"},{"key":"e_1_3_2_2_121_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.200800441"},{"key":"e_1_3_2_2_122_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm060236z"},{"key":"e_1_3_2_2_123_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.200800320"},{"key":"e_1_3_2_2_124_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-009-9294-9"},{"key":"e_1_3_2_2_125_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm1012819"},{"key":"e_1_3_2_2_126_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.09-148593"},{"key":"e_1_3_2_2_127_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2011.07.079"},{"key":"e_1_3_2_2_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2011.10.003"},{"key":"e_1_3_2_2_129_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e318237e5b7"},{"key":"e_1_3_2_3_2_1","unstructured":"Clinical Trials. www.clinicaltrials.gov"}],"container-title":["Future Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.4155\/fmc.12.29","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T19:51:19Z","timestamp":1716493879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.4155\/fmc.12.29"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":130,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["10.4155\/fmc.12.29"],"URL":"https:\/\/doi.org\/10.4155\/fmc.12.29","relation":{},"ISSN":["1756-8919","1756-8927"],"issn-type":[{"value":"1756-8919","type":"print"},{"value":"1756-8927","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}